<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A therapeutic trial of interleukin-3 (IL-3) was carried out in four patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> refractory to the prior therapies </plain></SENT>
<SENT sid="1" pm="."><plain>Daily subcutaneous doses of 2.5, 5.0 or 7.5 micrograms/kg was given for 7 or 14 days </plain></SENT>
<SENT sid="2" pm="."><plain>In a patient who had co- and immediate boost-administration of granulocyte colony-stimulating factor (G-CSF) and/or erythropoietin (Epo) and another who had sequential administration of G-CSF and Epo two weeks after IL-3, definite hematological response was obtained during the course after IL-3 </plain></SENT>
<SENT sid="3" pm="."><plain>In one patient, moderate to severe side effects consisting of <z:hpo ids='HP_0000282'>facial edema</z:hpo>, conjunctival <z:mp ids='MP_0001914'>bleeding</z:mp>, chills and <z:hpo ids='HP_0001945'>fever</z:hpo>, were observed after two days' administration of IL-3 </plain></SENT>
<SENT sid="4" pm="."><plain>Co- or sequential administration of other hemopoietic factor(s) may be essential in IL-3 therapy for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
</text></document>